janssen_latest_logo_on_sign

Janssen scores EU approval for blood cancer drug Darzalex

pharmafile | May 2, 2017 | News story | Manufacturing and Production, Sales and Marketing |  Europe, European Commission, Janssen, darzalex 

Janssen has announced that its CD38-directed monoclonal antibody Darzalex (daratumumab) has expanded its indication with a thumbs-up from the European Commission (EC) as a combination treatment for multiple myeloma in adult patients who have received at least one prior therapy.

The drug has been approved for use in combination with standards of care lenalidomide and dexamethasone, or bortezomib and dexamethasone. The approval means that Darzalex will made available very shortly to patients across Europe.

The decision to approve the drug was influenced by two Phase 3 studies which found that Darzalex reduced risk of disease progression or death when used in combination with standard of care therapies.

Advertisement

Dr Catherine Taylor, Haematology Therapeutic Area Lead for Janssen Europe, Middle East and Africa, explained: “This approval is an important step for people living with multiple myeloma across our region and offers some patients a new treatment option. We are encouraged by the data we have seen for daratumumab to date and will continue to investigate its potential.”

Matt Fellows

Related Content

Phoenix Labs acquires Kent Pharma

Phoenix Labs has acquired UK pharmaceutical distributor Kent Pharma from private equity firm Duke Street, …

Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases

Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) …

European Commission approves HIV prevention injection

The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first …

The Gateway to Local Adoption Series

Latest content